Human lipoproteinassociated phospholipase A2 ELIS productsSearch results for: Human lipoproteinassociated phospholipase A2 ELIS
#25173516 
//
To Up
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherogenesis through pathways related to inflammation. Darapladib is an oral, selective inhibitor of the Lp-PLA2 enzyme.Michelle L O'Donoghue, Eugene Braunwald, Harvey D White, Mary Ann Lukas, Elizabeth Tarka, P Gabriel Steg, Judith S Hochman, Christoph Bode, Aldo P Maggioni, KyungAh Im, Jennifer B Shannon, Richard Y Davies, Sabina A Murphy, Sharon E Crugnale, Stephen D Wiviott, Marc P Bonaca, David F Watson, W Douglas Weaver, Patrick W Serruys, Christopher P Cannon, , Dylan L Steen
